Jasper Therapeutics Inc. presented new data on briquilimab, its investigative drug for chronic urticaria, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The presentation highlighted rapid, deep, and durable efficacy, with mean UAS7 reductions greater than 25 points observed four weeks post-dose and up to a 92% complete response rate in certain cohorts. Safety and tolerability data from the BEACON and SPOTLIGHT studies showed that adverse events, mostly related to KIT blockade, were generally low grade and resolved with repeat dosing. Jasper Therapeutics also addressed ongoing investigations into confounded results from two BEACON study cohorts, noting that the issues were not related to the drug substance or product, and are conducting site and patient audits with additional data expected in late Q4 2025. Briquilimab is not approved for any indication at this time. You can access the full presentation through the link below.